Interrogating antiviral antibody responses with multiplexed, high-throughput serum assays
Hornick, A. C.; Walters, L. C.; Dobson, C. S.; Gaglione, S. A.; Birnbaum, M. E.
Show abstract
The COVID-19 pandemic underscored the importance of rapidly analyzing antibody responses against emerging viruses. Existing techniques, however, are limited in their ability to probe antibodies recognition of multiple native-conformation antigens simultaneously. To increase the throughput and multiplexability of antibody profiling, we developed Antibody Reactivity Characterization by Antibody-Dependent Enhancement (ARCADE). This assay employs an antigen-agnostic Fc receptor-expressing cell line and a library of antigen-displaying, genetically barcoded lentiviruses that, when mixed with serum, infect cells and integrate their barcodes at rates reflecting the relative abundances and affinities of the antigen-specific antibodies present. Verified using sera from COVID-19-convalescent and - vaccinated donors, ARCADE delivers insights that align with and expand upon those offered by established immunoassays, highlighting, for example, how an mRNA-based vaccine elicits broader and stronger antibody responses than an adenovirus vector-based vaccine. ARCADE can comprehensively assess how infection and vaccination impact antiviral antibody repertoires over time and across patient populations.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 95%
- A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo 95%
- BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants 95%
Similar papers in this journal
- Modular DNA Barcoding of Nanobodies Enables Multiplexed in situ Protein Imaging and High-throughput Biomolecule Detection 95%
- Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses 95%
- Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein after infection and/or vaccination 95%
Similar papers in this journal
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 95%
- Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection 95%
- Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.